EGFR and non-small cell lung carcinoma: Consistent with guidelines recommending EGFR-TKIs solely for patients with EGFR-mutated NSCLC [33], 12 patients with EGFR-mutant tumors were scheduled to receive EGFR-TKI therapy (11 with open-labeled treatment and 1 with closed-labeled treatment).